Erik Bogsch will remain Chairman of the Board, though.
As of 1 August.
Despite profit plunge.
Earnings report to be published this week.
Marketing of key drug green-lighted for Western Europe.
Key drug to hit shelves in Western Europe soon.
Nearly 20 billion forints worth of dividend will be paid.
Operating profit margin also seen higher.
Leading pharma reports robust Q1 results.
The rating is 'Overweight'.
Annual General Meeting to be held on 26 April.
There are only a handful of women in senior roles.
Magyar Telekom and OTP are the top picks.
'Buy' rating remains.
Profit doubled, yet share price is falling.
Analysts expect major profit growth for Q416.
Levosert goes to Europe.